Manulife Financial
A global life insurer with an Asia growth engine and a large wealth & asset-management arm — a capital-return story with a rising core ROE.
The business
Manulife is one of Canada's largest life insurers, operating in Canada, the U.S. (John Hancock) and — its key growth engine — Asia, plus Global Wealth & Asset Management (Manulife Investment Management).
It has de-risked its legacy long-term-care and legacy blocks through reinsurance, freeing capital for buybacks and dividends.
The moat
Scale, a strong Asian franchise and a capital-light wealth/asset-management business that compounds fee income.
Diversification across geographies and products smooths results.
Related on CoinCompass: Retirement drawdown calculator · TFSA vs RRSP. For the underlying numbers, see Manulife Q1 2026 results (StockTitan).
Financial snapshot
Most recent reported period : Q1 FY2026 (ended March 31, 2026). Figures reflect the review date — confirm current numbers before acting.
| Core earnings | C$1.84B |
| Core EPS | C$1.06 (+11% YoY) |
| Core ROE | 16.5% (target 18%+ by 2027) |
| LICAT capital ratio | 136% |
| Quarterly dividend | C$0.485 |
Free cash flow yield & sustainable growth
Earnings yield : ≈6.1%≈ earnings yield (trailing P/E ~16.4)
Free cash flow isn't a meaningful metric for a life insurer — Manulife is judged on core ROE, core-EPS growth, book value and regulatory capital (LICAT).
The engine here is a rising core ROE (16.5%, targeting 18%+ by 2027) and a very strong LICAT ratio of 136% — roughly C$25B above the supervisory target — which funds ongoing buybacks and dividend increases.
Sustainable growth: Asia new-business growth plus Global WAM fee income support mid-to-high-single-digit core-EPS growth, amplified per share by buybacks.
Valuation & what to watch
Life insurers are valued on core earnings, ROE and book value — not free cash flow. Manulife trades at a modest multiple with a solid dividend yield, reflecting its Asia leverage and improving returns.
The re-rating case is core ROE reaching the 18%+ target while capital keeps being returned.
Dividend
Pays a C$0.485 quarterly dividend after a ~10% hike in 2025; a 136% LICAT ratio and legacy de-risking underpin continued increases and buybacks.
Risks & the bear case
- Sensitivity to interest rates and equity markets (which drive both results and fee income).
- Asia macro and currency exposure.
- Legacy long-term-care blocks, though materially de-risked via reinsurance.
- Reported earnings can swing far from core earnings on market movements.
Recent developments
Q1 FY2026 core earnings of C$1.84B and core EPS of C$1.06 (+11%), with core ROE at 16.5% and LICAT at 136%; management reiterated an 18%+ core-ROE target by 2027.
Verdict
An improving-ROE, capital-return life insurer with real Asia and asset-management growth. The bull case is the ROE march to 18%+ plus buybacks; the bear case is market/rate sensitivity and Asia macro. Conviction: a reasonably-valued compounder-plus-income name for patient investors.
Sources
CoinCompass is a publisher, not a registered investment adviser. This is factual information and opinion for a general audience — not a recommendation to buy or sell any security, and not individualized advice. Figures are the most recent reported at the review date and will change. The author, John Wilson, has disclosed long-term holdings in Canadian equities (including Boyd Group, Constellation Software and MTY Food Group) and may hold positions in securities discussed. Do your own research or consult a licensed professional. See our disclosures. John Wilson → · disclosures →